ICI 170809, A selective 5-hydroxytryptamine antagonist, inhibits human platelet aggregation in vitro and ex vivo

  • Thomas P. Blackburn
  • Stephen J. Haworth
  • Carol L. Jessup
  • Pamela B. Morton
  • Christine Williams
Part of the Developments in CardioCardiovascular Pharmacology of 5-Hydroxytryptamine book series (DICM, volume 106)


In vitro 5-hydroxytryptamine (5-HT) cause both a shape and aggregation of human platelets. Few studies have been reported on 5-HT-induced platelet aggregation in patients with peripheral or cerebrovascular disease, although these patients have been reported to have enhanced platelet activity [1–6] and show hyperaggregability in response to known aggregating agents [7–9].


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Handin RI, McDough M, Lesch M. (1978): Elevation of platelet factor four in acute myocardial infarction: measurements by radioimmunoassay. J. Lab clin Med 91: 340–349.PubMedGoogle Scholar
  2. 2.
    Green LH, Scroppian E, Handin RI (1980): Platelet activation during exercise-induced myocardial ischaemia. New Engl J. Med 302: 193–197.PubMedCrossRefGoogle Scholar
  3. 3.
    Schwartz MB, Hangier J, Timmons S, Freisinger GC (1980): Platelet aggregates in ischaemic heart disease. Thromb Haemostasis 434: 185–188.Google Scholar
  4. 4.
    Baele G, Bogaerts H, Clements DL, Pannier peripheral arterial disease. Thromb Res 23: 215–223.Google Scholar
  5. 5.
    Rotmensch HH, Vlasses PH, Carpentier KL, D’Amelia LF, Swanson BN, Ferguson RK (1983): Plasma Platelet products and exercise-induced myocardial ischaema. J Lab clin Med 102: 63–69.PubMedGoogle Scholar
  6. 6.
    De Cree J, Leempoels J, Demoen B, Roels V, Verhaegen H (1985): The effects of ketanserin, a 5-HT2-receptor antagonist, on 5-hydroxytryptamine-induced irreversible platelet aggregation in patients with cardiovascular disease. Agents and Actions 16: 5, 313–317.PubMedCrossRefGoogle Scholar
  7. 7.
    Steele PP, Welly HS, Davies H, Genton E (1973): Platelet function studies in coronary artery disease. Circulation 48: 1194–1200.PubMedCrossRefGoogle Scholar
  8. 8.
    Dreyfuss F. Zahavi J (1973): adenosine diphospate-induced platelet aggregation in myocardial infarction and ischaemic heart disease. Atherosclerosis 17: 107–120.Google Scholar
  9. 9.
    Salky M, Dugdale M (1973): Platelet abnormalities in ischaemic heart disease. Am J Cardiol 32: 612–617.PubMedCrossRefGoogle Scholar
  10. 10.
    Blackburn TP, Thornber CW, Pearce RJ, Cox B, (1988): In vitro pharmacology of ICI 170,809 — A new 5-HT2antagonist. FASEB journal 2 (5):A1404,6441.Google Scholar
  11. 11.
    De Clerk F, van Neuten JM (1982): Platelet-mediated vascular contractions: Inhibition of the serotonergic component by ketanserin. Thrombs Res 27: 713–723.CrossRefGoogle Scholar
  12. 12.
    Nevelsteen A, Loots W, De Clerk F, De Gryse A (1984): Restoration of post-thrombotic peripheral collateral circulation in the cat by ketanserin, a selective 5-HT2receptor antagonist. Archs int Pharmacodyn Ther 270: 260–279.Google Scholar
  13. 13.
    Blackshear JL, Orlandi S, Garnic JD, Hollenberg NK (1983): Serotonin induces large artery spasm in vivo via 5-HT2 receptors. Circulation 68:III-197, Abs. 798.Google Scholar
  14. 14.
    Verheyen V, Vlaminckx E, Lauwers F, Van Den Broeck C, Wouters L (1984): Serotonin-induced blood flw changes in the rat hind legs after unilateral ligation of the femoral artery. Inhibition by the S2-receptor antagonist ketanserin. Pharmacodyn Ther 270: 280–294.Google Scholar
  15. 15.
    Hollenberg NK (1988): Serotonin and vascular responses. Ann rev Pharmacol Toxicol 28: 41–59.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1990

Authors and Affiliations

  • Thomas P. Blackburn
  • Stephen J. Haworth
  • Carol L. Jessup
  • Pamela B. Morton
  • Christine Williams

There are no affiliations available

Personalised recommendations